MedTrace Logo

Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers

NCT05518344 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-08-26

No results posted yet for this study

Summary

This is a clinical investigation. A total of up to 5 subjects, but not less than 3 at one investigational site will undergo insertion of the ISL in one eye and will be followed through 6 months postoperative.

Subjects from the United States will not be enrolled in this study.

Conditions

  • Myopia

Interventions

DEVICE

Viziatek ISL™ (hereinafter referred to as the "ISL") implanted in blind eye.

Viziatek ISL™ (hereinafter referred to as the "ISL") implanted in blind eye.

Sponsors & Collaborators

  • Hanita Lenses

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-04
Primary Completion
2022-03-16
Completion
2022-03-16

Countries

  • Latvia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518344 on ClinicalTrials.gov